jump to navigation

Clarus Ventures, life sciences VC firm, makes an investment in Lycera, a Michigan-based drug company working on auto-immune disease pharmaceuticals April 17, 2009

Posted by HubTechInsider in Venture Capital.
Tags: , ,
trackback

clarus417-thumb
Claris Ventures, a life sciences venture capital firm headquartered in Cambridge, was among firms co-leading a $36-million Series A financing round for Lycera Corp., a Michigan company looking to develop small-molecule drugs to treat auto-immune diseases.

In a press release, Lycera said that InterWest Partners and Arch Venture Partners joined Clarus Ventures in co-leading the financing.

In conjunction with the closing, Jeffrey Leiden, a Clarus managing director, has joined Lycera’s board of directors, along with representatives from Arch and InterWest, Lycera said.

The press release included a statement from Leiden, who said, “Lycera combines two of the most exciting new small-molecule approaches for treating autoimmune diseases.”

Comments»

No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: